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Background/aims. This study aims to determine the distribution and clinical features of HBV-genotypes in a population of
immigrants aﬀected by HBV-infection. Methods. Between 01/2003 and 03/2009, 1623 immigrants were tested for HBV-infection.
Biochemical and virological activities were determined in HBsAg-positive patients; HBV-genotypes were determined, by the
INNO-LiPA HBV Genotyping, in the subjects with HBV DNA detectable. In every patient we evaluated the stage and classiﬁed the
infection as inactive carrier, mild or moderate/severe chronic hepatitis, cirrhosis, and/or HCC. Results. Among the tested subjects,
191 (11.7%) resulted HBsAg-positive, and in 144/191 (75.4%) serum HBV-DNA was detectable. The genotype distribution was as
follows: 45,13% genotype E, 18,1% genotype D, 15,3% genotype B, 13,2% genotype C, 4,9% genotype A, 3,5% mixed genotypes
(A–D). The evaluation of liver disease degree showed that 24.6% patients were inactive carriers of HBV infection, 19.4% presented
a immunotolerance phase, 34.5% had mild chronic hepatitis, 13.6% had a moderate/severe chronic hepatitis, 6.3% had cirrhosis,
and1.6%presentedHCC.Conclusions.OurstudyevidencesahighprevalenceofHBV-infectioninimmigrants,andthepotentiality
of migratory ﬂow in the introduction of genotype non-D hepatitis B virus. The Hepatitis B virus genotypes presented signiﬁcant
diﬀerences in epidemiological and clinical characteristics.
1.Introduction
Hepatitis B virus (HBV) infection is a global health problem,
approximately 2 billion people in the world have been
infected by HBV, and more than 350 million are chronic
carriers of the virus. This infection is present mainly in some
countries as Middle-East and South-East Asia, sub-Saharan
Africa, Central and South-America, and East-Europe with a
prevalence >8% of population [1]. In the last twenty years
a migratory ﬂow has been going on from these countries to
the industrialized countries (USA and West-Europe) with an
increase of some infectious diseases (HIV, TB, viral hepatitis)
[2, 3].
The migratory ﬂow towards Italy has considerably
increased in the last 10 years: at present the total number
of legal immigrants can be estimated as 3.700.000 subjects
(6.2% of all population) [4]. When considering these ﬁgures,
it is obvious that, apart from questions regarding human
rights, social-economic, and cultural integration, the range
of health problems in immigrants is inevitably broad and
includes, mainly, infectious diseases.
In our precedent study, the acute or chronic viral
hepatitis represented the third cause of hospitalization for
infectious diseases in immigrants (12% of cases) after HIV
infection (16%) and tuberculosis (13%). The viral hepatitis
is most frequently related to HBV, particularly in African
people coming from sub-Saharan areas, and South-East, or
Far-East Asians [5].
But HBV infection is not always the same that we have
been knowing for years in Italy, it is often a new infection
with virological and clinical characteristics, HBV-genotypes
related.
The HBV genome is a partially double-stranded circular
DNA molecule consisting of 3200 nucleotides and exhibits
considerable genetic variability; based on a nucleotide
divergence >8% in the entire viral genome, HBV has been2 Hepatitis Research and Treatment
established and classiﬁed into eight genotypes (A to H)
with a characteristic geographic distribution. Genotype A
is widely distributed in North-West Europe, North-America
and Central Africa, while genotype B and C are present in
Asia only; genotype D has been found worldwide with its
highest prevalence in the Mediterranean area, the Middle
East, and South-Asia, particularly in India; genotype E is
found in Sub-Saharan Africa and genotype F in South and
Central America; genotype G has been found in France and
in the USA, while the newly discovered genotype H seems
so far to be restricted to the northern part of Latin America,
including Central America and Mexico [6, 7].
The accumulated evidences suggest that HBV genotypes
have an impact on the natural course of chronic HBV
infection with diﬀerences in the severity of underlying liver
disease or treatment response [8–10].
InItaly,about95%ofItalianpatientswithHBVinfection
presents the genotype D [6]. Since the migratory ﬂow
towards our country is coming from endemic areas for
HBV (prevalence >8%) such as East-Europe, sub-Saharan
Africa and East Asia, the introduction in Italy of nonD HBV
genotypes infection could be a natural consequence. This
maybeimportantbothfromtheepidemiologicalandclinical
point of view. In immigrants who live in diﬀerent districts
of Southern Italy the genotype distribution is strictly related
to the typology of immigration and reﬂects the distribution
for the areas of origin. In Campania and Lucania immigrants
are coming mainly from Middle East Asia and North Africa;
in Sicilia and Calabria from Middle East Asia, North Africa
and from Central Africa; in Puglia the immigration is mainly
from East Europe and from sub-Saharan Africa. In our
geographical area (Foggia) there are mainly immigrants
coming from Sub-Saharan Africa, East Europe and Far-
East Asia. The aim of the present study is to determine,
in a population of recent (<6 months) immigrants the
geographic distribution and virological characteristics of
HBV genotypes and the association between diﬀerent HBV
genotypes and the clinical status of patients.
2.MaterialsandMethods
Between January 2003 and March 2009 a total of 1623
volunteer immigrants (about 45% of total population) were
tested for infectious screening (HIV-HCV-TPHA-TB and
HBsAg-HBsAb-HBcAb of HBV) after obtaining appropriate
informedconsent.Alltestedsubjectsweretemporarilyguests
in a refugee camp managed by the Italian Red Cross, located
in Borgo Mezzanone (province of Foggia, Italy).
The study was reviewed and approved by the local
Chief of the Red Cross and written informed consent was
obtained from each study subject who was enrolled in the
study. All study procedures were in agreement with the
Helsinki Declaration (Edinburgh 2000). At enrolment, all
study participants were interviewed using a questionnaire
to obtain baseline demographic, clinical, and socioeconomic
information and to assess their previous exposure to HBV
Infection. All enrolled subjects also received a full clinical
examination and were treated accordingly.
The average length of staying in Italy was 2 months
(range 13–57 days) and the majority (1286, 79.3%) came
from Africa (41% Eritrea, 35% Somalia, 7.7% Liberia);
239 subjects (14.7%) came from Asia (8.8% Pakistan, 3.2%
China, 0.5% Iraq), while 98 subjects (6.0%) came from East-
Europe (3.8% Romania, 2.2% Albania).
The mean age of the tested subjects was 27.3 years
(range 1–56) and most of them were men (83.7%). We
evaluated, in HBsAg positive individuals, the biochemical
andvirologicalactivityofinfectionandtheeventualpresence
of coinfections (HCV, HDV, HIV); the HBVgenotype was
determined in those with detectable serum HBV-DNA.
HBsAg was assayed by commercial immunoassay (Abbott-
Auszyme Mc, Abbott Laboratories, North Chicago, IL,
USA). Hepatitis B E Antigen (HbeAg) and antibody to
HBeAg (anti-HBe) were detected by radioimmunoassay
(HBeAg/antiHBe immunoradiometric DiaSorin, Vercelli,
Italy). IgM and IgG anti-HDV were tested with commer-
cially available ELISA kits (Abbott Diagnostics, Weisbaden-
Delkenheim, Germany). The presence of antibodies to
HCV (anti-HCV) was determined by the use of a third-
generation enzyme-linked-immunoabsorbent assay (HCV-
ELISA, Ortho Diagnostic System, Raritan, NJ, USA) and
conﬁrmed by a third-generation-recombinant-immunoblot
assay (RIBA, Ortho Diagnostic Systems, Raritan, NJ, USA).
Antibodies to HIV (anti-HIV) were determined by EIA
(HIV1/HIV2, Abbott) and positive results were conﬁrmed
by Western Blot. Serum HBV-DNA levels were measured
by a commercial PCR-real time with a detection limit of
100copies/mL. Serum ALT was quantiﬁed by ultraviolet-
enzymatic-assay (normal range 0–40IU/L). For the deter-
mination of HBV genotypes, HBV-DNA was extracted
as described by Stuyver et al. [11]. The extracted DNA
was ampliﬁed over two rounds of PCR using biotinylated
PCR primers. After the two PCR for ampliﬁcation, HBV-
genotypes were determined by the INNO-LiPA HBV Geno-
typing (Innogenetics NV, Gent, Belgium). The correct HBV
genotype was determined by consulting an interpretation
chart showing probe reactivity patterns for each HBV
genotype.
3. Evaluation of Liver Disease Degree
All the patients with biochemical and/or virological activ-
ity of HBV infection refused to undergo liver biopsy.
Therefore, for the evaluation and classiﬁcation of liver
disease degree we considered several parameters: biliru-
bine, AST/ALT (ratio >1o r<1 in nonalcoholic patients),
viral load (<105 or >105 copies/mL), count of platelets
(>105/mm3 or <105/mm3), plasma proteins (hypoalbu-
minaemia, increased gammaglobulins), apolipoproteine A1,
aptoglobine, α2-macroglobuline, cholesterol, prothrombine
time, gamma-glutammil-transferase, pseudocholinesterasis,
abdominal echography. The disease degree was based on the
analysis of more variable parameters; only for hepatocellular
carcinoma (HCC) the main examen was the abdominal
echography, followed, after the ﬁrst diagnosis, by alpha-
phetoprotein and abdominal TC.Hepatitis Research and Treatment 3
The diﬀerent degrees of chronic hepatitis B can be
schematically divided into the following.
(1) “Immunotolerancephase”ischaracterizedbyHBeAg
positivity (wild type infection), high levels of HBV
replication (reﬂected by high levels of serum HBV
DNA), normal or low levels of aminotransferase,
mild or no liver necroinﬂammation and no or slow
progression of ﬁbrosis.
(2) Inactive HBV carrier state may follow seroconversion
from HBeAg to anti-HBe antibodies. It is character-
ized by very low or undetectable serum HBV DNA
levels and normal aminotransferase.
(3) Mild hepatitis: is marked by expansion of the portal
zone by mononuclear cells and some ﬁbrosis. The
limiting plate of liver cells between portal zones and
liver cell column is intact. Piecemeal necrosis of liver
cells is not seen.
(4) Moderate hepatitis is marked by the presence of an
inﬂammatory inﬁltrate, primarily of llymphocytes
and plasma cells, which greatly expands the portal
areas. The inﬂammatory inﬁltrate extends into the
liver lobule, causing erosion of the limiting plate and
piecemeal necrosis.
(5) Severe hepatitisis marked by ﬁbrous septa extending
intothelivercolumnswithisolationofgroupsofliver
cells in the form of rosettes. Intrahepatic “bridging”,
either portal-central or portal-portal, is seen.
4.StatisticalAnalysisMethods
To analyze the associations between genotypes (A, B, C, D,
E, and A-D mixed) and countries of origins, transaminases
levels (AST and ALT >40UI/mL), and stage of disease
(immunotollerance, mild hepatitis, moderate/severe hepati-
tis, cirrhosis, hepatocellular carcinoma), 2 × 2 contingence
tables were constructed and chi square (χ2)o rF i s h e rt e s tw a s
calculated. When it was possible, OR and its relative 95%
CI was calculated. To compare the levels of viremia among
diﬀerent genotypes, Kruskal-Wallis test was performed. The




positive, 146 males and 45 females. The mean age of positive
subjects was 26 years (range 19–47); 96 patients (50.2%)
came from Africa (30 from Liberia, 42 from Eritrea, and
24 from Somalia), 59 (31.0%) from Asia (38 from China
and 21 from Pakistan) and 36 (18.8%) from East-Europe
(19 from Romania and 17 from Albania). One hundred
and forty-eight patients were anti-HBe positive while 43
presented HBV wild (HBsAg-HBeAg positive) type. No
subject presented coinfection with HIV. Sixteen patients
showed coinfection with HDV, nine with HCV and three
with HCV-HDV. All the subjects with coinfection did not
present HCV and/or HDV viral replication.
Forty seven/191 (24.6%) patients presented normal
ALT levels (<40IU/L) and undetectable serum HBV DNA
(<100copies/mL), thirty-seven (19.4%) subjects presented
persistent normal ALT levels, but HBV-DNA detectable
by PCR Real Time (mean level 1374231copies/mL, range
74651–13.875.247), while 107 (56.0%) patients had elevated
ALT levels (mean level 141IU/L, range 68–297) and serum
HBV-DNA detectable (mean level 1561183copies/mL, range
22.933–11.290.865).
Genotype distribution, among all the HBV DNA positive
patients,wasdeterminedasfollows:65genotypeE(45.13%),
26 genotype D (18.1%), 22 genotype B (15.3%), 19 genotype
C (13.2%), 7 genotype A (4.9%), and 5 mixed genotypes
(A–D) (3.5%). Genotype E was associated to Eritrean (OR:
26.1, 95% CI: 7.2–139.2; χ2 = 41.96, P<. 001) and Liberian
subgroups (OR and 95% CI not calculable; χ2 = 31.56,
P<. 001). Genotype A was associated to Somali subgroup
(OR: 16.9, 95% CI: 2.4–126.5; χ2 = 18.85, P<. 001).
Genotypes C and B were associated to Chinese subgroup
(resp., OR: 39.1, 95% CI: 9.3–223.4; χ2 = 50.9, P<. 001
(OR: 14.1, 95% CI: 4.5–46.7; χ2 = 33.46, P<. 001).
Genotype D was associated to Pakistani (OR: 15.4, 95%
CI: 5.2–47.6; χ2 = 38.53, P<. 001) and to Albania
subgroups (OR and 95% CI: not calculable; χ2 = 38.44,
P<. 001). Also genotypes A–D mixed was associated to
Pakistani subgroup (OR and 95% CI: not calculable; χ2 =
17.42, P<. 001).
HBV wild type infection was present in 15/19 patients
with genotype C (78.9%), in 14/22 patients with genotype B
(63.6%), in 12/65 patients with genotype E (18.5%), and in
2/26 patients with genotype D (7.7%).
The mean ALT, in the patients with altered serum level,
was similar among the ﬁve diﬀerent genotypes (143 ±
37UI/mL.), without any association between any genotypes
and AST and ALT > 40UI/mL (P>. 05), respectively. The
level of HBV replication diﬀered between HBV genotypes,
withameanrateof1.5×106 copies/mL(range2.2×104–1.1×
107), with the highest values for genotype C and the lowest
meanvalues for genotype E (8.7×105 copies/mL). There was
a signiﬁcant diﬀerence in levels of viremia among diﬀerent
genotypes (χ2 = 54.47, P<. 001) (Table 1).
The evaluation of liver disease degree showed that 47/191
(24.6%) patients were inactive carriers of HBV infection,
37 presented a phase of immunotolerance, 66 (34.5%) had
mild chronic hepatitis, 26 (13.6%) had a moderate/severe
chronic hepatitis, 12/191 (6.3%) had cirrhosis and 3 (1.6%)
presented HCC. In Table 2 is shown the HBV infection
degree according to HBV genotypes.
There was not association between any genotypes and
immunotollerance state (P>. 05). Genotype E was associ-
ated with “mild chronic hepatitis” (OR: 4.2, 95% CI: 2–8.9;
χ2 = 16.84,P<. 001).Therewasnotassociationbetweenany
genotypes and “moderate/severe hepatitis or cirrhosis” (P>
.05).GenotypesA–Dmixedwasassociatedto“hepatocellular
carcinoma” (OR: 92, 95% CI: 3.2–5455.3; P<. 05).
Lookingatthethirty-eightpatientswithmoderate/severe
hepatitis or cirrhosis, in 20 of them (52.6%) the disease was
related to HBV wild infection, while 18 (47.4%) were anti-
HBe positive (P>. 05).4 Hepatitis Research and Treatment
Table 1: Distribution of HBV genotypes according to country of origin, mean of transaminase (P>. 05), and mean of viremia (P<. 001).
Genotypes Patients Country of origin Mean AST/ALT Mean HBV-DNA
levels (nv < 40UI/L) (nv < 20 copies/mL)
E 65 (45,13%)
33 Eritrea
124/150 871.900 22 Liberia
10 Somalia
D 26 (18,1%) 10 Romania
131/137 1.278.831 8 Albania
8 Pakistan
B 22 (15,3%) 15 China 132/143 1.176.900
7 Pakistan
C 19 (13,2%) 16 China 118/154 2.961.000
3 Pakistan
A 7 (4,9%) 4S o m a l i a 112/128 1.343.272
3E r i t r e a
MIxed (A/D) 5 (3,5%) 5 Romania 127/135 1.735.200
Table 2: HBV infection degree according to genotype, see the text.
Genotypes
ED B C A M i x e d
Immunotolerance P>. 05 16 7 9 3 2 0
Mild chronic hepatitis 42 9762 0
P<. 001
Moderate/severe chron. hepatitis P>. 05 7 6 4 5 2 2
Cirrhosis P>. 05 0 4 2 4 1 1
Hepatocarcinoma 2
Mixed P<. 05 0 0 0 1 0
6. Discussion
Some recent studies have shown how in immigrants HBV
infection represents one of the prevalent infectious diseases,
particularly in African people coming from sub-Saharan
areas [5, 7, 12, 13], with a rate of infection >8%, higher
than in Western Countries, probably caused by the lack or
incomplete prophylactic vaccination in the country of origin
and with risky sexual behaviour.
In our study we evaluated the prevalence, the typology
of HBV-infection and the degree of disease, according to
genotypes, in a population of immigrants to Italy, by a
mean period of 2 months. This is the ﬁrst study in Italy
which evaluates the stage of HBV chronic hepatitis according
to its viral genotype; previous studies had only showed
the heterogeneity of the virus according to the subjects’
geographical area [14, 15]. The results (HBsAg positive rate
of 11.7%) reﬂect the actual prevalent migratory ﬂow to
Italy, especially in our geographic area, mostly represented
by people coming from Africa [4]. An important ﬁnding
was that almost all HBsAg-positive subjects were men, but
this data could be related to the diﬃculty in testing females
(only 349/1623 of tested subjects were females). In fact, in
African communities females fear to know their eventual
diseases,particularlyinfectiousdiseaseswhichareconsidered
a further cause of social discrimination [5].
The vast majority of cases were infected by genotype E
and this coincides with the usual geographic distribution
of this genotype, which is exclusively diﬀused in sub-
Saharan areas [13]. Other HBV genotypes were also found
among immigrants to our country, like D-B-C-A and mixed
genotypes, thus reﬂecting diﬀerent areas of origin [11,
16, 17]. This redistribution of HBV genotypes represent
an important change in the epidemiology of infection,
increasing the number of infected subjects in our country,
with a “diﬀerent” hepatitis, also if the risk of contamination
with a “new virus” for Italian population is low, because the
HBV vaccination defends from a reinfection.
Recently, there have been several studies reporting the
inﬂuence of HBV genotypes on the clinical features [8, 9, 18]
and on the response to antiviral treatment (interferon and
lamivudine) of patients infected with HBV [10, 19, 20].
Therefore the diﬀerent genotypes, probably characterized by
adiﬀerentnaturalhistoryandadiﬀerentresponsetotherapy,
could require a diﬀerent clinical and therapeutic approach
compared to genotype-D. In order to further investigate
these associations, we have examined in our patients the
inﬂuence of HBV genotypes on the liver disease progression.
All the patients refused to undergo liver biopsy, therefore for
the evaluation and classiﬁcation of liver disease degree we
considered the noninvasive markers of ﬁbrosis and inﬂam-
mation in clinical practice, mainly the Fibrotest/Apritest,Hepatitis Research and Treatment 5
because the data of literature showed that these markers are
a reliable method for predicting signiﬁcant liver ﬁbrosis and
necroinﬂammation in both viral and nonviral chronic liver
disease patients.
Several tested subjects (about 25%) were inactive HBV
carriers. A normal ALT level ﬁnding is not surprising, since
HBV-infectionhasanhighprevalence(>8%)insub-Saharan
people, but many infected subjects (a variable rate of 40%–
65% in diﬀerent studies) do not show disease’s biochemical
activity [13].
The prevalence of immunotolerance phase and mild
chronic hepatitis was mainly observed in patients with
genotype E. This is absolutely usual given the origin of the
patients and the fact that at least part of them (and probably
not a small one) is supposed to have acquired HBV vertically
and thus might have developed immunotolerance to the
virus. These ones were all from Sub-Saharan Africa, where
HBV transmission mostly occurs during early childhood,
and were characterized by both a younger age and a lower
viral load than the other genotypes. Despite high endemicity,
little was known about HBV genotype distribution across
Africa until recently, when genotype E was found to be
characterized by a high prevalence and vast geographical
distribution (about one-third) in the African continent [21].
In a study among blood donors in Ghana, all infected
by genotype E, the mean viral load was relatively low even
in 16–19-years-old patients. Therefore the highest rate of
mild disease in genotype E, observed in our study, may be
related overall to younger age of infection and lower HBV-
DNA levels [22].
In conclusion, our study evidences a high prevalence of
HBV-infection in immigrants. The global migratory ﬂow to
our country, mainly from tropical areas, can determine a
partialmodiﬁcationofthenormalgeographicdistributionof
HBV-genotypes, with the introduction of nonD genotypes,
potentially characterized by diﬀerent natural history and
response to antiviral regimens.
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